Nonalcoholic steatohepatitis and the metabolic syndrome

American Journal of the Medical Sciences

Volumn 330, Issue 6, 2005, Pages 326-335

  Neuschwander Tetri, Brent A ^a  

^a Saint Louis University   (United States)

Author keywords

Alanine aminotransferase; Cirrhosis; Fatty liver; Insulin resistance; Liver biopsy

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; CORTICOSTEROID; GLITAZONE DERIVATIVE; HEPATITIS A VACCINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE; URSODEOXYCHOLIC ACID;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALCOHOL CONSUMPTION; AMINOTRANSFERASE BLOOD LEVEL; CAUSE OF DEATH; CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIET THERAPY; DRUG EFFICACY; DRUG TOLERABILITY; EXERCISE; HIGH RISK PATIENT; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID STORAGE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TOXICITY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; SIDE EFFECT; STOMACH BYPASS; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 29244444549     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200512000-00011     Document Type: Conference Paper

References (93)

1. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001;21:3-16.
2. Brunt EM. Nonalcoholic steatohepatitis. Semin Liver Dis 2004;24:3-20.
3. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-9.
4. Falck-Ytter Y, Younossi ZM, Marchesini G, et al. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001;21:17-26.
5. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003;124:71-9.
6. Ruhl CE, Everhart JE. Epidemiology of nonalcoholic fatty liver. Clin Liver Dis 2004;8:501-19.
7. García-Monzón C, Martín-Pérez E, Iacono OL, et al. Characterization of pathogenic and prognostic factors of non-alcoholic steatohepatitis associated with obesity. J Hepatol 2000;33:716-24.
8. Lavine JE, Schwimmer JB. Nonalcoholic fatty liver disease in the pediatric population. Clin Liver Dis 2004;8:549-58.
9. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990;12:1106-10.
10. Luyckx FH, Lefebvre PJ, Scheen AJ. Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss. Diabetes Metab 2000;26:98-106.
11. Willner IR, Waters B, Patil SR, et al. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001;96:2957-61.
12. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121:91-100.
13. Sanyal AJ, Campbell-Sargent C, Mirshani F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-92.
14. Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002;35:373-9.
15. Pagano G, Pacini G, Musso G, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002;35:367-72.
16. Chalasani N, Deeg MA, Persohn S, et al. Metabolic and anthropometric evaluation of insulin resistance in nondiabetic patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003;98:1849-55.
17. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003;37:1202-19.
18. Malnick SD, Beergabel M, Knobler H. Non-alcoholic fatty liver: a common manifestation of a metabolic disorder. QJM 2003;96:699-709.
19. Kral JG, Buckley MC, Kissileff HR, et al. Metabolic correlates of eating behavior in severe obesity. Int J Obesity 2001;25:258-64.
20. Garg A. Acquired and inherited lipodystrophies. N Engl J Med 2004;350:1220-34.
21. Brunt EM, Ramrakhiani S, Cordes BG, et al. Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease. Mod Pathol 2003;16:49-56.
22. Luyckx FH, Desaive C, Thiry A, et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 1998;22:222-6.
23. Ratziu V, Imbert-Bismut F, Messous D, et al. The elusiveness of "normal" ALT in fatty liver. Hepatology 2004;39:1172-3.
24. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003;98:960-7.
25. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137:1-9.
26. Kaplan MM. Alanine aminotransferase levels: what's normal? Ann Intern Med 2002;137:49-51.
27. Van Ness MM, Diehl AM. Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? Ann Intern Med 1989;111:473-8.
28. Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 1999;94:1018-22.
29. Loria P, Lonardo A, Leonardi F, et al. Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates. Dig Dis Sci 2003;48:2173-81.
30. Bianchi L. Liver biopsy in elevated liver functions tests? An old question revisited. J Hepatol 2001;35:290-4.
31. Mathiesen UL, Franzén LE, Frydén A, et al. The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients. Scand J Gastroenterol 1999;34:85-91.
32. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000;342:1266-71.
33. Skelly MM, James PD, Ryder SD. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol 2001;35:195-9.
34. Sorbi D, McGill DB, Thistle JL, et al. An assessment of the role of liver biopsies in asymptomatic patients with chronic liver test abnormalities. Am J Gastroenterol 2000;95:3206-10.
35. Siegelman ES, Rosen MA. Imaging of hepatic steatosis. Sem Liver Dis 2001;21:71-80.
36. Mortele KJ, Ros PR. Imaging of diffuse liver disease. Sem Liver Dis 2001;21:195-212.
37. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002;123:745-50.
38. Jacobs JE, Birnbaum BA, Shapiro MA, et al. Diagnostic criteria for fatty infiltration of the liver on contrast-enhanced helical CT. AJR Am J Roentgenol 1998;171:659-64.
39. Fukukura Y, Fujiyoshi F, Inoue H, et al. Focal fatty infiltration in the posterior aspect of hepatic segment IV: relationship to pancreaticoduodenal venous drainage. Am J Gastroenterol 2000;95:3590-5.
40. Aubin B, Denys A, Lafortune M, et al. Focal sparing of liver parenchyma in steatosis: role of the gallbladder and its vessels. J Ultrasound Med 1995;14:77-80.
41. Soyer P, Devine N, Somveille E, et al. Hepatic pseudolesion around the falciform ligament: prevalence on CT examination. Abdom Imaging 1996;21:324-8.
42. Hui JM, Kench J, Chitturi S, et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003;38:420-7.
43. McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2004;8:521-33.
44. Ioannou GN, Weiss NS, Kowdley KV, et al. Is obesity a risk factor for cirrhosis-related death or hospitalization? A population-based cohort study. Gastroenterology 2003;125:1053-9.
45. Sorrentino P, Tarantino G, Conca P, et al. Silent non-alcoholic fatty liver disease - a clinical-histological study. J Hepatol 2004;41:751-7.
46. Caldwell S, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol 2004;40:578-84.
47. Clark JM, Diehl AM. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA 2003;289:3000-4.
48. Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 2000;32:689-92.
49. Caldwell SH, Hespenheide EE. Obesity and cryptogenic cirrhosis. In: Leuschner U, James O, Dancygier H, editors. Steatohepatitis (ASH and NASH). Falk Symposium 121. Norwell, MA: Kluwer Academic Publishers; 2001. p. 151.
50. Ong J, Younossi ZM, Reddy V, et al. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl 2001;7:797-801.
51. Contos MJ, Cales W, Sterling RK, et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 2001;7:363-73.
52. Ratziu V, Bonyhay L, Di Martino V, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002;35:1485-93.
53. Nair S, Mason A, Eason J, et al. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology 2002;36:150-5.
54. Marrero JA, Fontana RJ, Su GI, et al. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002;36:1349-54.
55. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004;126:460-8.
56. Anagnostopoulos GK, Arvanitidis D, Tsiakos S, et al. Is hepatocellular carcinoma part of the natural history of nonalcoholic steatohepatitis? J Clin Gastroenterol 2003;37:88-9.
57. Yuan J-M, Govindarajan S, Arakawa K, et al. Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S. Cancer 2004;101:1009-17.
58. Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30:1356-62.
59. Day CP, James OF. Hepatic steatosis: innocent bystander or guilty party? Hepatology 1998;27:1463-6.
60. Washington K, Wright K, Shyr Y, et al. Hepatic stellate cell activation in nonalcoholic steatohepatitis and fatty liver. Hum Pathol 2000;31:822-8.
61. Cortez-Pinto H, Baptista A, Camilo ME, et al. Hepatic stellate cell activation occurs in nonalcoholic steatohepatitis. Hepatogastroenterol 2001;48:87-90.
62. Paradis V, Perlemuter G, Bonvoust F, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001;34:738-44.
63. Latry P, Bioulac-Sage P, Echinard E, et al. Perisinusoidal fibrosis and basement membrane-like material in the livers of diabetic patients. Hum Pathol 1987;18:775-80.
64. Marceau P, Biron S, Hould F-S, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999;84:1513-7.
65. Angulo P, Lindor KD. Treatment of nonalcoholic fatty liver: present and emerging therapies. Sem Liver Dis 2001;21:81-8.
66. Lindor KD, Kowdley KV, Heathcote EJ, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004;39:770-8.
67. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.
68. Center for Disease Control and Prevention Primary Prevention Working Group. Primary prevention of type 2 diabetes mellitus by lifestyle intervention: implications for health policy. Ann Intern Med 2004;140:951-7.
69. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
70. Hu FB, Li TY, Colditz GA, et al. Television watching and other sedentary behaviours in relation to risk of obesity and type 2 diabetes mellitus in women. JAMA 2003;289:1785-91.
71. Gauthier MS, Couturier K, Latour JG, et al. Concurrent exercise prevents high-fat-diet-induced macrovesicular hepatic steatosis. J Appl Physiol 2003;94:2127-34.
72. Kugelmas M, Hill DB, Vivian B, et al. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003;38:413-9.
73. Wang RT, Koretz RL, Yee HF, Jr. Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review. Am J Med 2003;115:554-9.
74. Foster GD, Wyatt HR, Hill JO, et al. A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med 2003;348:2082-90.
75. Samaha FF, Iqbal N, Seshadri P, et al. A low-carbohydrate as compared with a low-fat diet in severe obesity. N Engl J Med 2003;348:2074-81.
76. Bonow RO, Eckel RH. Diet, obesity, and cardiovascular risk. N Engl J Med 2003;348:2057-8.
77. Polyzogopoulou EV, Kalfarentzos F, Vagenakis AG, et al. Restoration of euglycemia and normal acute insulin response to glucose in obese subjects with type 2 diabetes following bariatric surgery. Diabetes 2003;52:1098-103.
78. Mun EC, Blackburn GL, Matthews JB. Current status of medical and surgical therapy for obesity. Gastroenterology 2001;120:669-81.
79. Steinbrook R. Surgery for severe obesity. N Engl J Med 2004;350:1075-9.
80. Ranløv I, Hardt F. Regression of liver steatosis following gastroplasty or gastric bypass for morbid obesity. Digestion 1990;47:208-14.
81. Marceau P, Hould FS, Lebel S, et al. Malabsorptive obesity surgery. Surg Clin North Am 2001;81:1113-27.
82. Duchini A, Brunson ME. Roux-en-Y gastric bypass for recurrent nonalcoholic steatohepatitis in liver transplant recipients with morbid obesity. Transplantation 2001;72:156-71.
83. Kral JG, Thung SN, Biron S, et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 2004;135:48-58.
84. Tiikkainen M, Hakkinen A-M, Korsheninnikova E, et al. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004;53:2169-76.
85. Caldwell SH, Hespenheide EE, Redick JA, et al. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001;96:519-25.
86. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone. Hepatology 2003;38:1008-17.
87. Shadid S, Jensen MD. Effect of pioglitazone on biochemical indices of non-alchoholic fatty liver disease in upper body obesity. Clin Gastroenterol Hepatol 2003;1:384-7.
88. Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004;39:188-96.
89. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Interim results of a pilot study demonstrating the early effects of the PPAR-γ ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J Hepatol 2003;38:434-40.
90. Marchesini G, Brizi M, Bianchi G, et al. Metformin in non-alcoholic steatohepatitis [letter]. Lancet 2001;358:893-4.
91. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000;136:734-8.
92. Harrison SA, Torgerson S, Hayashi P, et al. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003;98:2485-90.
93. Chalasani N, Aljadhey H, Kesterson J, et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004;126:1287-92.